Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan 1;27(1):5-7.
doi: 10.1158/1078-0432.CCR-20-3506. Epub 2020 Oct 26.

Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy

Joyce K Hwang  1 , Neeraj Agarwal  2 , James Brugarolas  3 , Tian Zhang  4   5   6
Affiliations
Comment

Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy

Joyce K Hwang et al. Clin Cancer Res. .

Abstract

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.See related article by Tannir et al., p. 78.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Molecular mutations common in sarcomatoid renal cell carcinoma and interactions with tumor microenvironment driving sensitivity to immune checkpoint inhibitors. TME: tumor microenvironment; NK: natural killer cells; Treg: regulatory T-cells. Adapted from Wang et al., Clinical Cancer Research, 2017 (10).
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Abdallah F, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2020. - PMC - PubMed
    1. Debien V, Thouvenin J, Lindner V, Barthélémy P, Lang H, Flippot R, et al. Sarcomatoid dedifferentiation in renal cell carcinoma: From novel molecular insights to new clinical opportunities. Cancers (Basel). 2020. - PMC - PubMed
    1. Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020; 8(2): e000891; - PMC - PubMed
    1. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019;
    1. Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, et al. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. Eur Urol. 2020; - PMC - PubMed

Publication types